Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using Tb-149-rituximab
Нема приказа
Аутори
Beyer, GJMiederer, M
Vranješ-Đurić, Sanja
Čomor, Jožef J.
Kunzi, G
Hartley, O
Senekowitsch-Schmidtke, R
Soloviev, D
Buchegger, F
Чланак у часопису
Метаподаци
Приказ свих података о документуАпстракт
This study demonstrates high-efficiency sterilisation of single cancer cells in a SCID mouse model of leukaemia using rituximab, a monoclonal antibody that targets CD20, labelled with terbium-149, an alpha-emitting radionuclide. Radio-immunotherapy with 5.5 MBq labelled antibody conjugate (1.11 GBq/mg) 2 days after an intravenous graft of 5.10(6) Daudi cells resulted in tumour-free survival for GT 120 days in 89% of treated animals. In contrast, all control mice (no treatment or treated with 5 or 300 mug unlabelled rituximab) developed lymphoma disease. At the end of the study period, 28.4%+/-4% of the long-lived daughter activity remained in the body, of which 91.1% was located in bone tissue and 6.3% in the liver. A relatively high daughter radioactivity concentration was found in the spleen (12%+/-2%/g), suggesting that the killed cancer cells are mainly eliminated through the spleen. This promising preliminary in vivo study suggests that targeted alpha therapy with Tb-149 is worthy... of consideration as a new-generation radio-immunotherapeutic approach.
Кључне речи:
alpha particle-emitting radionuclides / terbium-149 / radio-immunotherapy / rituximab / leukaemiaИзвор:
European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 4, 547-554
DOI: 10.1007/s00259-003-1413-9
ISSN: 1619-7070
PubMed: 14722680
WoS: 000220298600013
Scopus: 2-s2.0-1842714861
Колекције
Институција/група
VinčaTY - JOUR AU - Beyer, GJ AU - Miederer, M AU - Vranješ-Đurić, Sanja AU - Čomor, Jožef J. AU - Kunzi, G AU - Hartley, O AU - Senekowitsch-Schmidtke, R AU - Soloviev, D AU - Buchegger, F PY - 2004 UR - https://vinar.vin.bg.ac.rs/handle/123456789/2757 AB - This study demonstrates high-efficiency sterilisation of single cancer cells in a SCID mouse model of leukaemia using rituximab, a monoclonal antibody that targets CD20, labelled with terbium-149, an alpha-emitting radionuclide. Radio-immunotherapy with 5.5 MBq labelled antibody conjugate (1.11 GBq/mg) 2 days after an intravenous graft of 5.10(6) Daudi cells resulted in tumour-free survival for GT 120 days in 89% of treated animals. In contrast, all control mice (no treatment or treated with 5 or 300 mug unlabelled rituximab) developed lymphoma disease. At the end of the study period, 28.4%+/-4% of the long-lived daughter activity remained in the body, of which 91.1% was located in bone tissue and 6.3% in the liver. A relatively high daughter radioactivity concentration was found in the spleen (12%+/-2%/g), suggesting that the killed cancer cells are mainly eliminated through the spleen. This promising preliminary in vivo study suggests that targeted alpha therapy with Tb-149 is worthy of consideration as a new-generation radio-immunotherapeutic approach. T2 - European Journal of Nuclear Medicine and Molecular Imaging T1 - Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using Tb-149-rituximab VL - 31 IS - 4 SP - 547 EP - 554 DO - 10.1007/s00259-003-1413-9 ER -
@article{ author = "Beyer, GJ and Miederer, M and Vranješ-Đurić, Sanja and Čomor, Jožef J. and Kunzi, G and Hartley, O and Senekowitsch-Schmidtke, R and Soloviev, D and Buchegger, F", year = "2004", abstract = "This study demonstrates high-efficiency sterilisation of single cancer cells in a SCID mouse model of leukaemia using rituximab, a monoclonal antibody that targets CD20, labelled with terbium-149, an alpha-emitting radionuclide. Radio-immunotherapy with 5.5 MBq labelled antibody conjugate (1.11 GBq/mg) 2 days after an intravenous graft of 5.10(6) Daudi cells resulted in tumour-free survival for GT 120 days in 89% of treated animals. In contrast, all control mice (no treatment or treated with 5 or 300 mug unlabelled rituximab) developed lymphoma disease. At the end of the study period, 28.4%+/-4% of the long-lived daughter activity remained in the body, of which 91.1% was located in bone tissue and 6.3% in the liver. A relatively high daughter radioactivity concentration was found in the spleen (12%+/-2%/g), suggesting that the killed cancer cells are mainly eliminated through the spleen. This promising preliminary in vivo study suggests that targeted alpha therapy with Tb-149 is worthy of consideration as a new-generation radio-immunotherapeutic approach.", journal = "European Journal of Nuclear Medicine and Molecular Imaging", title = "Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using Tb-149-rituximab", volume = "31", number = "4", pages = "547-554", doi = "10.1007/s00259-003-1413-9" }
Beyer, G., Miederer, M., Vranješ-Đurić, S., Čomor, J. J., Kunzi, G., Hartley, O., Senekowitsch-Schmidtke, R., Soloviev, D.,& Buchegger, F.. (2004). Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using Tb-149-rituximab. in European Journal of Nuclear Medicine and Molecular Imaging, 31(4), 547-554. https://doi.org/10.1007/s00259-003-1413-9
Beyer G, Miederer M, Vranješ-Đurić S, Čomor JJ, Kunzi G, Hartley O, Senekowitsch-Schmidtke R, Soloviev D, Buchegger F. Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using Tb-149-rituximab. in European Journal of Nuclear Medicine and Molecular Imaging. 2004;31(4):547-554. doi:10.1007/s00259-003-1413-9 .
Beyer, GJ, Miederer, M, Vranješ-Đurić, Sanja, Čomor, Jožef J., Kunzi, G, Hartley, O, Senekowitsch-Schmidtke, R, Soloviev, D, Buchegger, F, "Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using Tb-149-rituximab" in European Journal of Nuclear Medicine and Molecular Imaging, 31, no. 4 (2004):547-554, https://doi.org/10.1007/s00259-003-1413-9 . .